Drug Profile
Research programme: androgen receptor antagonists - Medivation
Alternative Names: MDV 300 series; MDVN 300 seriesLatest Information Update: 23 Mar 2012
Price :
$50
*
At a glance
- Originator University of California at Los Angeles
- Developer Medivation
- Class Small molecules
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 23 Mar 2012 No development reported - Preclinical for Prostate cancer in USA (unspecified route)
- 29 Jun 2007 Medivation receives clearance from the FDA to commence a phase I/IIa trial of MDV 3100 in hormone-refractory prostate cancer
- 01 Mar 2007 Preclinical data added to the Cancer pharmacodynamics section